Registered title, quoted from ClinicalTrials.gov
ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07481669, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Males or females unwilling to use contraception from consent signature until 6 months after completion of study treatment.
Exclusion criterion 11
Creatinine clearance (Cockcroft-Gault) ≥ 50 mL/min / serum creatinine ≤ 1.5 mg/dL
Inclusion criterion 9
ALT and AST < 2.5 × upper limit of normal (ULN)
Inclusion criterion 10
Total bilirubin < 1.5 × ULN
Inclusion criterion 11
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L
Inclusion criterion 12
Platelet count ≥ 100 × 10⁹/L
Inclusion criterion 13
Concurrent malignancy or life-threatening disease; or prior malignancy cured < 2 years.
Exclusion criterion 2
Negative serum or urine pregnancy test for females of childbearing potential (females who have undergone sterilization or are postmenopausal for ≥ 2 years are considered non childbearing). All patients must practice effective contraception during study treatment.
Inclusion criterion 17
Pregnant or breastfeeding females.
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07481669, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histopathologically confirmed systemic non-Hodgkin lymphoma at initial diagnosis and meets one of the following:
- CNS IPI score (4-6 points)
- kidney or adrenal gland involvement
- testis or breast involvement
- primary cutaneous DLBCL, leg type
- CR or PR after induction therapy
- Age 18-70 years.
- Adequate renal, hepatic, pulmonary, hematologic, and cardiac function:
- Creatinine clearance (Cockcroft-Gault) ≥ 50 mL/min / serum creatinine ≤ 1.5 mg/dL
- ALT and AST < 2.5 × upper limit of normal (ULN)
- Total bilirubin < 1.5 × ULN
- Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L
- Platelet count ≥ 100 × 10⁹/L
- Left ventricular ejection fraction ≥ 50%; no clinically significant pericardial effusion or ECG abnormalities
- No clinically significant pleural effusion
- Baseline oxygen saturation ≥ 95% at rest on room air
- Negative serum or urine pregnancy test for females of childbearing potential (females who have undergone sterilization or are postmenopausal for ≥ 2 years are considered non childbearing). All patients must practice effective contraception during study treatment.
- Able to comply with the study protocol per investigator judgment.
- Voluntary participation, understanding study procedures, and provision of written informed consent; For illiterate patients (potentially vulnerable population), a literate family member must be present and provide written consent.
Exclusion Criteria:
- Diagnosis of primary central nervous system lymphoma (PCNSL).
- Concurrent malignancy or life-threatening disease; or prior malignancy cured < 2 years.
- Grade ≥ 2 mucositis.
- Congestive heart failure, uncontrolled hypertension, or unstable cardiovascular disease.
- Uncontrolled infection.
- Uncontrolled progressive disease during the study.
- Prior allogeneic hematopoietic stem cell transplantation.
- Any condition that may interfere with safety or efficacy assessment.
- Severe hypersensitivity to any study drug.
- Pregnant or breastfeeding females.
- Males or females unwilling to use contraception from consent signature until 6 months after completion of study treatment.
- Unlikely to complete all required study visits/procedures (including follow up) per investigator judgment.
Quoted from ClinicalTrials.gov, NCT07481669, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07481669, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.